Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases

病毒学核心与其他内部NIAID实验室合作开发MERS-CoV刺突蛋白亚单位疫苗。佐剂MERS-CoV刺突蛋白亚单位疫苗的疫苗赋予羊驼对MERS-CoV疾病的完全保护，并导致单峰骆驼上呼吸道中病毒脱落减少和延迟。这些数据表明，通过对未接种动物接种疫苗诱导强大的中和体液免疫应答减少了散毒，这可能会降低人畜共患病传播的风险。 在过去的一年里，我们专注于从SARS-CoV、MERS-CoV和HKU-1感染患者中分离单克隆抗体，并接种非人灵长类动物。分析单克隆抗体对不同冠状病毒的结合和中和能力。本研究成功地评估了一些具有高效价和呼吸的抗冠状病毒单克隆抗体。 这些单克隆抗体在抗感染方面可能具有潜在的治疗应用。

The Virology Core has collaborated with other intramural NIAID labs to develop a MERS-CoV Spike protein subunit vaccine. A vaccine of adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. The data indicate that induction of robust neutralizing humoral immune responses by vaccination of nave animals reduces shedding that potentially could diminish the risk of zoonotic transmission. During the past year, we focused on isolation of monoclonal antibodies from SARS-CoV, MERS-CoV, and HKU-1 infected patients and vaccinated non-human primates. The monoclonal antibodies were analyzed for their binding and neutralization ability against different coronaviruses. This study successfully assessed some anti-coronavirus monoclonal antibodies with high potency and breath. Those monoclonal antibodies may have potential therapeutic application in fighting infection.